Format

Send to

Choose Destination
Expert Rev Anticancer Ther. 2007 Apr;7(4):447-59.

Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor.

Author information

1
National Cancer Institute, Pediatric Oncology Branch, Bethesda, MD 20892, USA. foxb@mail.nih.gov

Abstract

P-glycoprotein actively transports structurally unrelated compounds out of cells, conferring the multidrug resistance phenotype in cancer. Tariquidar is a potent, specific, noncompetitive inhibitor of P-glycoprotein. Tariquidar inhibits the ATPase activity of P-glycoprotein, suggesting that the modulating effect is derived from the inhibition of substrate binding, inhibition of ATP hydrolysis or both. In clinical trials, tariquidar is tolerable and does not have significant pharmacokinetic interaction with chemotherapy. In patients, inhibition of P-glycoprotein has been demonstrated for 48 h after a single dose of tariquidar. Studies to assess a possible increase in toxicity of chemotherapy and the impact of P-glycoprotein inhibition on tumor response and patient outcome are ongoing. Tariquidar can be considered an ideal agent for testing the role of P-glycoprotein inhibition in cancer.

PMID:
17428165
DOI:
10.1586/14737140.7.4.447
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center